Sanofi-Aventis v. Teva Pharmaceuticals USA, Inc.

356 F. App'x 388
Court of Appeals for the Federal Circuit·Decided July 30, 2009·No. No. 2007-1521·Published

Opinion

ON MOTION

ORDER

MAYER, Circuit Judge.

Sanofí-Aventis et al. (Sanofi) submit correspondence that the court treats as a motion for summary affirmance and issuance of the mandate. Sanofi states that Teva Pharmaceuticals USA, Inc. consents.

[389] This appeal was stayed pending the court’s disposition of Sanofi-Aventis v. Apotex, 2007-1438. In Apotex, the court affirmed the district court’s ruling that Sanofi’s patent was not invalid. Sanofi states that Sanofi and Teva agree that, in light of the court’s disposition in Apotex, this appeal should be disposed of by issuance of a mandate affirming the trial court’s decision.

Accordingly,

IT IS ORDERED THAT:

(1) The motion is granted. The judgment of the United States District Court for the Southern District of New York is summarily affirmed and the mandate is issued herewith.

(2) Each side shall bear its own costs.

Free access — add to your briefcase to read the full text and ask questions with AI

Sanofi-Aventis v. Teva Pharmaceuticals USA, Inc., 356 F. App'x 388 (Fed. Cir. 2009).

356 F. App'x 388 (Sanofi-Aventis v. Teva Pharmaceuticals USA, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.